Amneal receives u.s. fda approval for bimatoprost ophthalmic solution, 0.01%

Bridgewater, n.j., sept. 23, 2025 (globe newswire) -- amneal pharmaceuticals, inc. (“amneal” or the “company”) today announced that the u.s. food and drug administration (fda) has approved the company's abbreviated new drug application (anda) for bimatoprost ophthalmic solution 0.01% (2.5 ml, 5 ml and 7.5 ml).
AMRX Ratings Summary
AMRX Quant Ranking